Neo Biopharm ApS: Financial statements 2023
CVR: 42875708
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Neo Biopharm ApS (CVR 42875708) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 528,359 and a net result of DKK 243,802. Equity in the 2023 report amounted to DKK 2,108,709. The solvency ratio was 76.8%.
- Gross Profit
- DKK 528,359
- Profit/Loss
- DKK 243,802
- Equity
- DKK 2,108,709
- Total Assets
- DKK 2,745,273
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Neo Biopharm ApS has published its interim report for the period November 23, 2021 to December 31, 2022.
About Neo Biopharm ApS
Neo Biopharm ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Amirhossein Saadatirad and Jakob Juul Rasmussen. The company is owned by Maryam Badri. In 2025, the company reported a gross profit of DKK -357,308 and a net result of DKK -271,403 compared with DKK 157,190 the year before. Equity in the 2025 report amounted to DKK 1,994,496.